Related Experiment Video
Updated: Jun 14, 2025
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
Ketamine infusion for pain control in severely injured patients: Results of a randomized controlled trial
Thomas W Carver1, William J Peppard, Jaclyn A Gellings
1From the Division of Trauma and Critical Care Surgery, Department of Surgery (T.W.C., W.J.P., J.A.G., C.T., M.M.-W., J.R.P., M.E.S., D.J.M., A.F.E., M.A.d.M., T.A.d.R-C.), Division of Regional Anesthesia and Acute Pain Management (R.T.), and Division of Biostatistics, Institute for Health & Equity (A.S., Y.Y.), Medical College of Wisconsin, Milwaukee, Wisconsin.
Background:
Opiate-based pain regimens remain the cornerstone of pain management following traumatic injury, but issues related to opioids have driven research into alternative analgesics. Adjunctive ketamine has been increasingly used to decrease opioid use, but little evidence exists to support its efficacy within the trauma population.
Methods:
A prospective, randomized, double-blind placebo-controlled trial of severely injured (Injury Severity Score [ISS], ≥15) adult patients (aged 18-64 years) admitted to a Level 1 trauma center was conducted. Exclusion criteria included Glasgow Coma Scale score of <14, ISS of <15, pregnancy, and chronic opiate use. All patients were prescribed a patient-controlled analgesia in addition to being randomized to either adjustable dose ketamine starting at 3 μg/kg/min or an equivalent rate of 0.9% normal saline. Study drug and patient-controlled analgesia titration were allowed as part of a treatment algorithm. The primary outcome was reduction in oral morphine equivalent (OME) utilization at 24 hours.
Results:
We performed a planned interim analysis upon reaching a predetermined enrollment goal. Forty-two of 78 patients (53.8%) were randomized to the experimental arm. Both groups were similar in makeup and had a median ISS of 22 (19, 28.5). The median OMEs in adjustable dose ketamine and placebo groups were 110.6 (55.7, 191.7) and 99.2 (50.6, 172.6), respectively ( p = 0.85). No significant difference in OME was found in 24- to 48-hour or the entire 48-hour study period. Adjustable dose ketamine had no impact on pain scores throughout the study period when compared with placebo (4.9 vs. 4.7, p = 0.95). These findings met the futility cutoff, and enrollment was terminated.
Conclusion:
Adjustable dose ketamine failed to reduce OME totals or pain scores in a severely injured trauma cohort when compared with placebo at any time point. Additional studies are necessary to determine if there is any benefit for adjuvant ketamine in different trauma subpopulations.
Level Of Evidence:
Therapeutic/Care Management; Level I.
